Drug intelligence / Profile preview

PF-03084014 + docetaxel

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

PF-03084014 + docetaxel is a combination therapy consisting of PF-03084014 (also known as nirogacestat), a selective, small-molecule γ-secretase inhibitor, and docetaxel, a well-established taxane chemotherapeutic agent. PF-03084014 inhibits the γ-secretase complex, thereby blocking NOTCH receptor activation and downstream signaling pathways implicated in tumor growth and survival. Docetaxel disrupts microtubule function during cell division, leading to apoptosis in rapidly dividing cancer cells. This combination is under investigation for synergistic antitumor effects in advanced solid tumors.

Other names: nirogacestat + docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))NOTCH (Neurogenic locus notch homolog protein 3)GSEC (Gamma-Secretase Complex)

Beyond the preview

Go deeper on PF-03084014 + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-03084014 + docetaxel.

Explore the full profile